🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
The purpose of this study is to determine the maximum tolerated dose (MTD) ...
Status
Terminated
Location
University of Arizona Cancer Center, Tucson
Start Date
2017-03-05
Trial ID
NCT02954406
Treatments Being Tested
This is a Phase 2a, multicenter, open-label uncontrolled study aimed at det...
Status
Unknown
Location
Ospedale San Raffaele
Start Date
2017-11-08
Trial ID
NCT04754035
Treatments Being Tested
Combination study of monalizumab (IPH2201) with Ibrutinib in relapsed, refr...
Status
Terminated
Location
The Ohio State University Wexner Medical Center
Start Date
2015-11-09
Trial ID
NCT02557516
Treatments Being Tested
This is Phase I pilot, single center study designed to explore the safety o...
Status
Terminated
Location
Dana Farber Cancer Institute
Start Date
2019-11-04
Trial ID
NCT04115059
Treatments Being Tested
This is an open-label, Phase 2 study designed to assess the efficacy and sa...
Status
Completed
Location
Providence Saint Joseph Medical Center
Start Date
2013-12
Trial ID
NCT01980654
Primary Objectives The primary objective of this study is to evaluate the e...
Status
Unknown
Location
Klinikum der Universität München
Start Date
2016-04
Trial ID
NCT02689869
This study evaluates the safety and efficacy of daratumumab in combination ...
Status
Terminated
Location
Weill Cornell Medicine
Start Date
2020-07-30
Trial ID
NCT03679624
Treatments Being Tested
TP-0903 is an inhibitor of AXL kinase. TP-0903 has shown potent inhibition ...
Status
Terminated
Location
Mayo Clinic Arizona
Start Date
2019-06-10
Trial ID
NCT03572634
Treatments Being Tested
The purpose of this study is to evaluate the efficacy and safety of Ibrutin...
Status
Unknown
Location
Multiple Locations
Start Date
2021-10-01
Trial ID
NCT04994626
Treatments Being Tested
SNX-5422 is a prodrug of SNX-2112, a potent, highly selective, small molecu...
Status
Withdrawn
Location
Wexner Medical Center, Ohio State University
Start Date
2017-02-02
Trial ID
NCT02914327
Treatments Being Tested